Wave Life Sciences Ltd. (WVE)
WVE Stock Price Chart
Explore Wave Life Sciences Ltd. interactive price chart. Choose custom timeframes to analyze WVE price movements and trends.
WVE Company Profile
Discover essential business fundamentals and corporate details for Wave Life Sciences Ltd. (WVE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Nov 2015
Employees
287.00
Website
https://www.wavelifesciences.comCEO
Paul B. Bolno
Description
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
WVE Financial Timeline
Browse a chronological timeline of Wave Life Sciences Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.30.
Earnings released on 30 Jul 2025
EPS came in at -$0.31 falling short of the estimated -$0.29 by -6.90%, while revenue for the quarter reached $8.70M , missing expectations by -11.69%.
Earnings released on 8 May 2025
EPS came in at -$0.29 falling short of the estimated -$0.27 by -7.41%, while revenue for the quarter reached $9.18M , missing expectations by -36.35%.
Earnings released on 4 Mar 2025
EPS came in at $0.17 surpassing the estimated -$0.17 by +200.00%, while revenue for the quarter reached $83.75M , beating expectations by +588.34%.
Earnings released on 12 Nov 2024
EPS came in at -$0.47 falling short of the estimated -$0.28 by -67.86%, while revenue for the quarter reached -$7.68M , missing expectations by -129.99%.
Earnings released on 8 Aug 2024
EPS came in at -$0.25 falling short of the estimated -$0.16 by -56.25%, while revenue for the quarter reached $19.69M , missing expectations by -19.06%.
Earnings released on 9 May 2024
EPS came in at -$0.24 falling short of the estimated -$0.18 by -33.33%, while revenue for the quarter reached $12.54M , missing expectations by -45.37%.
Earnings released on 6 Mar 2024
EPS came in at -$0.15 surpassing the estimated -$0.19 by +21.05%, while revenue for the quarter reached $29.06M , beating expectations by +46.30%.
Earnings released on 9 Nov 2023
EPS came in at $0.07 surpassing the estimated -$0.18 by +138.89%, while revenue for the quarter reached $49.21M , beating expectations by +147.80%.
Earnings released on 3 Aug 2023
EPS came in at -$0.20 surpassing the estimated -$0.32 by +37.50%, while revenue for the quarter reached $22.11M , beating expectations by +178.41%.
Earnings released on 3 May 2023
EPS came in at -$0.27 falling short of the estimated $0.06 by -550.00%, while revenue for the quarter reached $12.93M , missing expectations by -60.01%.
Earnings released on 22 Mar 2023
EPS came in at -$0.47 falling short of the estimated -$0.42 by -11.90%, while revenue for the quarter reached $1.24M , missing expectations by -82.45%.
Earnings released on 10 Nov 2022
EPS came in at -$0.42 surpassing the estimated -$0.48 by +12.50%, while revenue for the quarter reached $285.00K , missing expectations by -96.52%.
Earnings released on 11 Aug 2022
EPS came in at -$0.62 falling short of the estimated -$0.56 by -10.71%, while revenue for the quarter reached $375.00K , missing expectations by -90.22%.
Earnings released on 12 May 2022
EPS came in at -$0.62 falling short of the estimated -$0.56 by -10.71%, while revenue for the quarter reached $1.75M , missing expectations by -54.63%.
Earnings released on 3 Mar 2022
EPS came in at -$0.61 falling short of the estimated -$0.47 by -29.79%, while revenue for the quarter reached $1.77M , missing expectations by -88.82%.
Earnings released on 10 Nov 2021
EPS came in at -$0.12 surpassing the estimated -$0.64 by +81.25%, while revenue for the quarter reached $36.42M , missing expectations by -38.70%.
Earnings released on 5 Aug 2021
EPS came in at -$0.78 falling short of the estimated -$0.61 by -27.87%, while revenue for the quarter reached $2.78M , missing expectations by -71.64%.
Earnings released on 13 May 2021
EPS came in at -$0.86 falling short of the estimated -$0.56 by -53.57%.
Earnings released on 4 Mar 2021
EPS came in at -$0.59 falling short of the estimated -$0.55 by -7.27%, while revenue for the quarter reached $9.44M .
Earnings released on 9 Nov 2020
EPS came in at -$0.86 falling short of the estimated -$0.73 by -17.81%, while revenue for the quarter reached $3.45M , beating expectations by +32.69%.
WVE Stock Performance
Access detailed WVE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.